3SBio's stock price soared 5.10% during intraday trading on Friday, reflecting strong investor interest in the biopharmaceutical company.

The surge follows the presentation of positive clinical data for the company's core pipeline asset, the PD-1/VEGF bispecific antibody SSGJ-707, at the ASCO Annual Meeting. According to published abstracts, a Phase II study of SSGJ-707 monotherapy in advanced non-small cell lung cancer demonstrated a confirmed objective response rate of 67.6% and a median progression-free survival of 12.4 months. Another Phase II study combining the therapy with chemotherapy as a first-line treatment for endometrial cancer showed confirmed objective response rates of 85.7% and 80.0%, respectively.

The movement occurred alongside a broader rally in the biotechnology sector, highlighting strong market sentiment for innovative drug developers. The news also comes amid a sustained boom in licensing deals within China's biotech industry, with global pharmaceutical companies actively seeking partnerships.